NeuroMetrix, Inc. (NURO) Stock Analysis & Investment Frameworks
NeuroMetrix, Inc. (NURO) stock analysis on Invetso. Review NeuroMetrix, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
NeuroMetrix, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
NeuroMetrix, Inc. Key Financial Metrics
- Market Cap: $9.43M
- Revenue: $3.03M
- ROE: -45.38%
- ROIC: -60.91%
- Dividend Yield: N/A
About NeuroMetrix, Inc.
NeuroMetrix, Inc. is a healthcare company focused on creating, manufacturing, and distributing medical devices that stimulate and evaluate nerve function for both diagnostic and therapeutic applications. These products are available across a wide geographical area, including the United States, Europe, Japan, China, the Middle East, and Mexico. The company's core offerings include DPNCheck, a nerve conduction test used to identify and assess peripheral neuropathies such as diabetic peripheral neuropathy; Quell, a wearable device engineered for the relief and management of persistent pain; and the ADVANCE system, a dedicated platform for performing comprehensive nerve conduction studies. NeuroMetrix supplies its advanced solutions to a diverse clientele, encompassing managed care organizations, primary care providers, specialists like endocrinologists, podiatrists, various surgeons (including orthopedic and hand surgeons), occupational health practitioners, and neurology, pain medicine, and physical medicine and rehabilitation experts. Incorporated in 1996, the company's headquarters are located in Woburn, Massachusetts.